Armour Thyroid's Phase 3 Trial in Hypothyroidism Reads Out
ESTIMÉCONFIANCE 50 %ClinicalTrials.gov[1] gives the primary completion date only as 2027-09, an estimate by the sponsor, so the pin sits on the first of that month.
AbbVie's phase 3 trial of Armour Thyroid in hypothyroidism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,800 participants. This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
1.00